Advancing the Therapeutic Potential of Epitranscriptomics: Storm’s Firstin- Class METTL3 Inhibitor, STC-15

Time: 9:45 am
day: Conference Day Two

Details:

• Preclinical data demonstrates that modulating RNA methylation via METTL3 inhibition can enhance tumor sensitivity to treatment and impair resistance mechanisms

• Epitranscriptomic regulation produces durable changes to gene expression and the tumor microenvironment, suggesting anti-cancer efficacy through multiple mechanisms

• STC-15 clinical and translational data point to broad utility of METTL3 inhibition, enabling new treatment approaches across oncology indications

Speakers:

Jerry McMahon
Jerry McMahon Jerry has over 30 years of biotechnology leadership, scientific innovation, creative deal-making, and financing experience. With broad disease-area expertise and a specialty in oncology therapeutics, Read more